The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

OcuTerra Therapeutics has reported that its Phase II DR:EAM clinical trial of selective RGD integrin inhibitor nesvategrast (OTT166) eye drops for patients with diabetic retinopathy (DR ...

Background Implementing lipid control in patients with diabetes is regarded as a potential strategy for halting the advancement of diabetic retinopathy (DR ... and full-course DR (background DR, ...

Diabetic retinopathy is a common complication in people with type 1 and type 2 diabetes, progressing from mild, moderate, and severe non-proliferative diabetic retinopathy to proliferative diabetic ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...

Immunofluorescence analysis revealed more intense transforming growth factor β2 (TGFβ2) and connective tissue growth factor (CTGF) staining in IVB-treated proliferative diabetic retinopathy (PDR ...